1254980-09-0

Basic information

• Product Name: 8-(trifluoromethyl)-3-(cyclopropylmethyl)-7-[(4-phenyl-4-methoxy-1-piperidinyl)methyl]-[1,2,4]triazolo[4,3-a]pyridine
• Synonyms: 8-(trifluoromethyl)-3-(cyclopropylmethyl)-7-[(4-phenyl-4-methoxy-1-piperidinyl)methyl]-[1,2,4]triazolo[4,3-a]pyridine
• CAS NO: 1254980-09-0
• Molecular Weight: 444.5
• Mol File: 1254980-09-0.mol

Chemical Properties

• CAS DataBase Reference: 8-(trifluoromethyl)-3-(cyclopropylmethyl)-7-[(4-phenyl-4-methoxy-1-piperidinyl)methyl]-[1,2,4]triazolo[4,3-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 8-(trifluoromethyl)-3-(cyclopropylmethyl)-7-[(4-phenyl-4-methoxy-1-piperidinyl)methyl]-[1,2,4]triazolo[4,3-a]pyridine(1254980-09-0)
• EPA Substance Registry System: 8-(trifluoromethyl)-3-(cyclopropylmethyl)-7-[(4-phenyl-4-methoxy-1-piperidinyl)methyl]-[1,2,4]triazolo[4,3-a]pyridine(1254980-09-0)

Safety Data

• Hazardous Substances Data: 1254980-09-0(Hazardous Substances Data)

Upstream product

• 1254982-03-0 3-(cyclopropylmethyl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine-7-carbaldehyde 
• 1254981-30-0 7-chloro-3-(cyclopropylmethyl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine 
• 83949-38-6 4-methoxy-4-phenylpiperidine hydrochloride 
• 1254982-05-2 7-((methylsulfonyloxy)methyl)-3-(cyclopropylmethyl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine 
• 1254982-04-1 7-(hydroxymethyl)-3-(cyclopropylmethyl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine 

Relevant articles and documents

Discovery of 8-Trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine (JNJ-46356479), a Selective and Orally Bioavailable mGlu2 Receptor Positive Allosteric Modulator (PAM)

Positive allosteric modulators of the metabotropic glutamate 2 receptor have generated great interest in the past decade. There is mounting evidence of their potential as therapeutic agents in the treatment of multiple central nervous system disorders. We have previously reported substantial efforts leading to potent and selective mGlu2 PAMs. However, finding compounds with the optimal combination of in vitro potency and good druglike properties has remained elusive, in part because of the hydrophobic nature of the allosteric binding site. Herein, we report on the lead optimization process to overcome the poor solubility inherent to the advanced lead 6. Initial prototypes already showed significant improvements in solubility while retaining good functional activity but displayed new liabilities associated with metabolism and hERG inhibition. Subsequent subtle modifications efficiently addressed those issues leading to the identification of compound 27 (JNJ-46356479). This new lead represents a more balanced profile that offers a significant improvement on the druglike attributes compared to previously reported leads.

1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.